KalVista Pharmaceuticals has licensed commercialisation rights for sebetralstat, an oral on-demand treatment for hereditary ...
As KalVista Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has ...
1d
Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening ...
Dr. Sheri Yolanda Prentiss explores the challenges patients face in accessing lymphedema compression garments following ...
MedPage Today on MSN2d
Alzheimer's Lecanemab Treatment Up to 36 Months Supported by Extension StudyBiomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early ...
Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback